News headlines about Bellicum Pharmaceuticals (NASDAQ:BLCM) have trended somewhat negative this week, Accern reports. The research group identifies positive and negative news coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Bellicum Pharmaceuticals earned a coverage optimism score of -0.03 on Accern’s scale. Accern also assigned headlines about the biopharmaceutical company an impact score of 45.591243989835 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
These are some of the headlines that may have impacted Accern’s scoring:
- Bellicum Pharmaceuticals (BLCM) Given New $27.00 Price Target at Citigroup (americanbankingnews.com)
- BLCM LOSS NOTICE: Rosen Law Firm Reminds Bellicum Pharmaceuticals, Inc. Investors of Important Deadline in Class Action – BLCM (finance.yahoo.com)
- SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Bellicum Pharmaceuticals, Inc. (BLCM) & Lead Plaintiff Deadline – April 9, 2018 (finance.yahoo.com)
- SHAREHOLDER ALERT: Pawar Law Group Announces a Securities Class Action Lawsuit Against Bellicum Pharmaceuticals, Inc. – BLCM (finance.yahoo.com)
- Federman & Sherwood Announces Filing of Securities Class Action Lawsuit Against Bellicum Pharmaceuticals, Inc. (forextv.com)
A number of brokerages recently weighed in on BLCM. Zacks Investment Research upgraded shares of Bellicum Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, October 24th. Raymond James Financial restated a “buy” rating on shares of Bellicum Pharmaceuticals in a research report on Tuesday, December 12th. ValuEngine upgraded shares of Bellicum Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Wednesday, January 3rd. BidaskClub upgraded shares of Bellicum Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Thursday, January 4th. Finally, Wells Fargo & Co downgraded shares of Bellicum Pharmaceuticals from an “outperform” rating to a “market perform” rating and set a $6.00 price objective on the stock. in a research report on Wednesday, January 31st. Two equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and five have issued a buy rating to the company. The stock has an average rating of “Hold” and an average target price of $16.88.
Shares of Bellicum Pharmaceuticals (BLCM) traded up $0.63 during trading on Friday, reaching $6.60. 1,220,000 shares of the company were exchanged, compared to its average volume of 1,030,000. The company has a market capitalization of $242.65, a P/E ratio of -2.21 and a beta of 0.70. Bellicum Pharmaceuticals has a 12 month low of $5.02 and a 12 month high of $15.55. The company has a current ratio of 6.08, a quick ratio of 6.08 and a debt-to-equity ratio of 0.23.
In other Bellicum Pharmaceuticals news, major shareholder Bros. Advisors Lp Baker sold 880,735 shares of the company’s stock in a transaction that occurred on Friday, January 19th. The shares were sold at an average price of $8.20, for a total transaction of $7,222,027.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Alan A. Musso sold 17,117 shares of the company’s stock in a transaction that occurred on Monday, December 11th. The shares were sold at an average price of $9.33, for a total transaction of $159,701.61. Following the sale, the chief financial officer now directly owns 31,585 shares of the company’s stock, valued at $294,688.05. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 1,165,145 shares of company stock worth $9,696,662. 18.77% of the stock is owned by insiders.
WARNING: This piece of content was reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this piece of content on another site, it was illegally copied and reposted in violation of US and international copyright & trademark law. The legal version of this piece of content can be read at https://ledgergazette.com/2018/02/17/bellicum-pharmaceuticals-blcm-receiving-somewhat-critical-media-coverage-analysis-finds.html.
Bellicum Pharmaceuticals Company Profile
Bellicum Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system.
Receive News & Ratings for Bellicum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.